<DOC>
	<DOCNO>NCT00397839</DOCNO>
	<brief_summary>Male osteoporosis common important clinical problem , associate significant morbidity , mortality societal expense . Approximately 10 % men =65 year age osteoporotic . The propose study evaluate efficacy safety oral ibandronate give 150 mg once-monthly 12 month versus placebo men primary osteoporosis . Less frequent , monthly , dose expect improve patient 's treatment adherence compare weekly dose regimen .</brief_summary>
	<brief_title>The Effect Of Oral Ibandronate In Male Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : Ambulatory men least 30 year old screening , diagnose primary , idiopathic hypogonadal osteoporosis accord follow criterion : Femoral neck ( FN ) BMD Tscore &lt; 2.0 LS BMD Tscore &lt; 1.0 OR LS BMD Tscore &lt; 2.0 FN BMD Tscore &lt; 1.0 BMD Tscore &gt; 4.0 site Subjects , opinion investigator , willing able comply protocol requirement Subjects sign informed consent Exclusion criterion : Significant medical condition laboratory abnormality , opinion investigator may preclude patient 's ability complete study Malignant disease diagnose within previous 5 year ( except resect basal cell cancer ) Disease/disorder know influence bone metabolism cause secondary osteoporosis e.g. , chronic gastrointestinal liver disease , renal disease , chronic alcoholism , malabsorption syndrome Hypersensitivity component ibandronate Inability stand sit upright position least 60 minute Inability swallow tablet without break Vitamin D deficiency ( serum 25OH vitamin D &lt; 20ng/mL ( equivalent 50nmol/L ) screen Any prevalent osteoporotic vertebral fracture identify total spine xray ( Total spine xray consist lateral PA film thoracic &amp; lumbar spine ) Subjects receive testosterone supplementation &lt; 2 year ( applicable ) ( Patients identify clinical sign hypogonadism screen start testosterone supplementation exclude participation . ) Contraindications calcium vitamin D therapy Administration investigational drug within 30 day precede first dose study drug Previous treatment oral bisphosphonate within last six month , OR one month cumulative treatment within last year , OR three month cumulative treatment within last two year AND/OR treatment intravenous bisphosphonate within one year . Treatment PTH similar anabolic agent osteoporosis within last two year Treatment drug affect bone metabolism within last six month prior Screening include : Chronic systemic glucocorticoid treatment except topical treatment frequency twice per week Calcineurin inhibitor [ e.g. , cyclosporine , tacrolimus ] methotrexate Testosterone therapy ( unless stabilize medication &gt; 2 year ) Calcitonin Fluoride ( dose great 10mg/day ) strontium osteoporosis within last 12 month , past treatment total 2 year Selective estrogen receptor modulators ( SERMS ) raloxifene , toremifene , tamoxifen , arzoxifene lasofoxifene Anabolic steroid androgen , dehydroepiandrosterone ( DHEA ) sulphated form ( DHEAs ) Active vitamin D analogs/metabolites as1,25dihydroxy vitamin D ( calcitriol ) 1alphahydroxy vitamin D3 ( 1 alpha hydroxycholecalciferol ) Gonadotropin release antagonist ( lupron ) ALT &gt; twice upper limit normal range central laboratory Hypercalcemia uncorrected hypocalcemia : Serum total Ca 2+ &gt; 10.5mg/dl &lt; 8.0 mg/dL ( equivalent 2.6 2.0 mmol/L ) GFR &lt; 30 ml/min determine estimate creatinine clearance ( CLcr ) calculate CockcroftGault equation : CLcr = ( 140age ) * ABW X 0.85 72*Scr : CLcr estimate creatinine clearance Age year ABW actual body weight screen ( kg ) Scr serum creatinine screening ( mg/dL ) History major upper GI disease define : Significant upper GI bleeding within last year require hospitalization transfusion Recurrent peptic ulcer disease document radiographic endoscopic mean Dyspepsia gastroesophageal reflux uncontrolled medication Abnormalities esophagus delay esophageal emptying , stricture , achalasia , dysmotility Active gastric/duodenal ulcer Dyspepsia control daily medication OR prior history nonrecurrent peptic ulcer disease consider exclusionary WBC &lt; 2500/ÂµL Serum albumin &lt; 3.0g/dL History hyperthyroidism , hyperparathyroidism osteomalacia within one year study entry Fewer three ( 3 ) vertebra range L1L4 evaluable DXA . Conditions interfere BMD measurement include prevalent fracture , sequelae orthopedic procedure ( e.g. , spinal fusion , metal implant , etc . ) , severe scoliosis severe degenerative change ( e.g. , osteophytes , sclerosis ) Bilateral hip replacement Any restriction , define site requirement hrMRI procedure ( subset hrMRI subject )</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>male osteoporosis</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bisphonates</keyword>
	<keyword>bone</keyword>
</DOC>